Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 9:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 1,989 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Alzheimer Disease Dementia Clear all
Completed Phase 2 Interventional

Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Prolonged Open Label Extension Phase

NCT01602393
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
CHF 5074 1x, CHF 5074 2x, CHF 5074 3x
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
18 Years to 79 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
4
States / cities
Eatontown, New Jersey • Monroe Twp, New Jersey • Toms River, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2014 · Synced Oct 16, 2026, 9:05 AM EDT
Completed Phase 2 Interventional

Phase 2 Estimation Study of Fixed Dose Drugs Combination Type of Polypill

NCT06597058
View directory record Official record
Conditions
Alzheimer Disease
Interventions
MAR
Drug
Lead sponsor
Noah Pharmaceuticals, Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
16
States / cities
Scottsdale, Arizona • Huntington Beach, California • DeLand, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 16, 2026, 9:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Sound Estimation and Accuracy Task

NCT02271685
View directory record Official record
Conditions
Parkinson's, Alzheimer Disease
Interventions
Instructions about Overestimates, Instructions about Parkinson's, Instructions about Underestimates, Instructions about Alzheimers
Other
Lead sponsor
Carnegie Mellon University
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 21, 2015 · Synced Oct 16, 2026, 9:05 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Sleep Trial to Prevent Alzheimer's Disease

NCT04629547
View directory record Official record
Conditions
Sleep, Alzheimer Disease
Interventions
Suvorexant 20 mg, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
65 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 16, 2026, 9:05 AM EDT
Not yet recruiting Not applicable Interventional

The Care for America's Aging Study

NCT06021704
View directory record Official record
Conditions
Cognitive Impairment, Dementia With Behavioral Disturbance, Dementia, Alzheimer Disease
Interventions
Enhanced home health aide training in dementia and dementia-related behaviors
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
60 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 16, 2026, 9:05 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

DELPHI in Subjects at Risk for Stroke and Dementia

NCT03884647
View directory record Official record
Conditions
Stroke, Hypertension, Diabete Mellitus, Dyslipidemias, Sleep Disorder, Smoking, Overweight and Obesity, Familial Alzheimer Disease, Atrial Fibrillation, Cardiac Disease, Cognitive Impairment, Transient Ischemic Attack
Interventions
DELPhI system
Device
Lead sponsor
QuantalX Neuroscience
Industry
Eligibility
50 Years to 75 Years
Enrollment
335 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
3
States / cities
Walnut Creek, California • Atlanta, Georgia • Norwood, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 14, 2022 · Synced Oct 16, 2026, 9:05 AM EDT
Withdrawn Not applicable Interventional

Study of Magnetic Fields to Treat Alzheimer's Disease

NCT01313806
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Resonator, Placebo
Device
Lead sponsor
pico-tesla Magnetic Therapies, LLC
Industry
Eligibility
55 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Denver, Colorado • Clearwater, Florida
Source: ClinicalTrials.gov public record
Updated May 30, 2011 · Synced Oct 16, 2026, 9:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Study to Determine the Bioavailability of E2609 Tablets Compared to Capsules and the Effect of Food on Absorption

NCT01716897
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
E2609
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
30 Years to 55 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated May 22, 2013 · Synced Oct 16, 2026, 9:05 AM EDT
Completed Phase 1 Interventional

Safety and Tolerability of Dimebon in Patients on Memantine, and Memantine Plus Donepezil

NCT00829816
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Dimebon, Placebo
Drug
Lead sponsor
Medivation, Inc.
Industry
Eligibility
50 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
4
States / cities
Los Alamitos, California • National City, California • Delray Beach, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2015 · Synced Oct 16, 2026, 9:05 AM EDT
Completed Phase 1 Interventional

Efavirenz for Patients With Alzheimer's Disease

NCT03706885
View directory record Official record
Conditions
Alzheimer Disease, Early Onset
Interventions
Sustiva Pill
Drug
Lead sponsor
Case Western Reserve University
Other
Eligibility
55 Years to 85 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Beachwood, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Oct 16, 2026, 9:05 AM EDT
Completed Phase 3 Interventional

Memory Impairment Study (Mild Cognitive Impairment Study)

NCT00000173
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Donepezil, Vitamin E
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
55 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
63
States / cities
Phoenix, Arizona • Tucson, Arizona • Irvine, California + 53 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2009 · Synced Oct 16, 2026, 9:05 AM EDT
Terminated Phase 3 Interventional Results available

A Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer's Disease (AD).

NCT02670083
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Crenezumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 85 Years
Enrollment
813 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
66
States / cities
Phoenix, Arizona • Encino, California • Long Beach, California + 56 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2020 · Synced Oct 16, 2026, 9:05 AM EDT
Not listed Phase 2 Interventional

Levetiracetam for Alzheimer's Disease Neuropsychiatric Symptoms Related to Epilepsy Trial (LAPSE)

NCT04004702
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Levetiracetam
Drug
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
Not listed
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2019 · Synced Oct 16, 2026, 9:05 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Couples Lived Experience

NCT04863495
View directory record Official record
Conditions
Alzheimer Disease, Dementia of Alzheimer Type
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
65 Years and older
Enrollment
544 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
2
States / cities
Bedford, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 16, 2026, 9:05 AM EDT
Completed Phase 1 Interventional

Automated Retinal Image Analysis System (EyeQuant) for Computation of Vascular Biomarkers

NCT04567745
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer Disease, Vascular Dementia
Interventions
Retinal fundus photography
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 16, 2026, 9:05 AM EDT
Completed Not applicable Interventional

Music Therapy Experiences in Patients With Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD)

NCT04666077
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Home-based MT through Supervised, Supported Singing (H3S), Individualized Music Therapy (IMT), Attention Control (AtCon)
Behavioral · Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
55 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 16, 2026, 9:05 AM EDT
Completed Early Phase 1 Interventional Results available

The INCREASE Study - Delaying the Onset of Alzheimer's Symptomatic Expression

NCT02849639
View directory record Official record
Conditions
Alzheimer's Disease, Dementia
Interventions
Placebo, Medication Therapy Management (MTM), Scopolamine patch
Other · Drug
Lead sponsor
Daniela Moga
Other
Eligibility
65 Years to 101 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Oct 16, 2026, 9:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction (DDI) w/Ketoconazole or Fluconazole

NCT00860275
View directory record Official record
Conditions
Alzheimer Disease
Interventions
BMS-708163, BMS-708163 + Ketoconazole, Ketoconazole, Fluconazole, BMS-708163 + Fluconazole
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 25, 2011 · Synced Oct 16, 2026, 9:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Memory Functions in Mild Alzheimer's Disease

NCT04785053
View directory record Official record
Conditions
Alzheimer Disease
Interventions
transcranial alternating current stimulation (tACS)
Device
Lead sponsor
Hebrew SeniorLife
Other
Eligibility
21 Years and older
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Oct 16, 2026, 9:05 AM EDT
Completed Phase 2 Interventional Results available

Tau Screening Study in Subjects With Early Symptomatic AD

NCT03467477
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Flortaucipir F18, Brain PET Scan
Drug · Procedure
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
60 Years to 85 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
9
States / cities
Irvine, California • Delray Beach, Florida • Fort Myers, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2020 · Synced Oct 16, 2026, 9:05 AM EDT
Active, not recruiting Phase 3 Interventional

A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD

NCT06709014
View directory record Official record
Conditions
Early Alzheimers Disease
Interventions
buntanetap/posiphen, Placebo
Drug
Lead sponsor
Annovis Bio Inc.
Industry
Eligibility
55 Years to 85 Years
Enrollment
760 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
78
States / cities
Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 16, 2026, 9:05 AM EDT
Completed Phase 2 Interventional Results available

Observational Study of Cognitive Outcomes for Subjects Who Have Had Prior PET Amyloid Imaging With Florbetapir F 18 (18F-AV-45)

NCT00857506
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
8
States / cities
Scottsdale, Arizona • Tucson, Arizona • Costa Mesa, California + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2013 · Synced Oct 16, 2026, 9:05 AM EDT
Completed Not applicable Interventional Results available

Smart Lighting for Nursing Home Residents With Dementia

NCT05825404
View directory record Official record
Conditions
Alzheimer's Disease and Related Dementias
Interventions
Smart Ambient Bright Light (SABL), Control
Device · Other
Lead sponsor
Penn State University
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
2
States / cities
Belleville, Pennsylvania • DuBois, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 8, 2025 · Synced Oct 16, 2026, 9:05 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)

NCT06653153
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Remternetug, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years to 80 Years
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
123
States / cities
Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 108 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 16, 2026, 9:05 AM EDT